Sanofi says biotech acquisitions will help overcome diabetes decline
French pharma makes move into haemophilia market.
After losing out on two big deals, Sanofi to buy Bioverativ for $11.6bn
2017 could be a bumper year for M&A – but Trump’s price control threats dominate
Despite Trump price concerns, JP Morgan event anticipates M&A boom
Coming antibody drugs and gene therapy could transform treatment
Biogen’s haemophilia spin-out Bioverativ to launch early 2017
New haemophilia drug Elocta approved in Europe